An Analysis of Antibody Response to COVID-19 Vaccination Among Medicos in a Predominantly Tribal State in India: A Comparative Study

• Published in: Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e61154
• Main Authors: Kiran, Kumari Asha, Kumari, Sushma, Saroj, Usha, Kujur, Manisha, Kujur, Anit, Kumar, Mithilesh, Narain, Smiti, N, Venkatesh, K, Jeseena
• Format: Article
• Language: English
• Subjects: Antibodies; COVID-19 vaccines; Females; Gender; Infections; Infectious Disease; Laboratories; Pandemics; Preventive Medicine; Public Health; Severe acute respiratory syndrome coronavirus 2; Students
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.61154

Introduction Global health is still being impacted by the coronavirus disease 2019 (COVID-19) pandemic. Objectives We evaluated the antibody response in this study in individuals who received two doses of the COVID-19 vaccination, both with and without a history of SARS-CoV-2 infection. Methodology It was a hospital-based cross-sectional study conducted among healthcare personnel at a tertiary institution of a predominantly tribal state in India. Results A total of 187 medical students made up the vaccinee group; the majority (152; 81.3%) were between the ages of 18 and 23; 128 (68.4%) of the students were female; and 104 (55.6%) had received the Covishield (AstraZeneca plc, England, UK) vaccination. Of the subjects, 51 (27.3%) had a history of COVID-19 infection. For those who were infected, the antibody titer peaked after six months, whereas it took twice as long for those who were not. Up to a year later, the antibody titers for Covaxin (Bharat Biotech, Hyderabad, India) and Covishield remained equal; however, Covishield titers drastically decreased while Covaxin stayed constant when an infection history was present. Conclusion The study's findings show that immunization in individuals who have previously contracted COVID-19 induces a higher level of antibody response than immunization in individuals who have not previously contracted the virus.